Skip to main content
Erschienen in: Infection 4/2019

17.05.2019 | Case Report

Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient

verfasst von: Nancy Law, Cathy Logan, Gordon Yung, Carrie-Lynn Langlais Furr, Susan M. Lehman, Sandra Morales, Francisco Rosas, Alexander Gaidamaka, Igor Bilinsky, Paul Grint, Robert T. Schooley, Saima Aslam

Erschienen in: Infection | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

We describe the use of bacteriophage therapy in a 26-year-old cystic fibrosis (CF) patient awaiting lung transplantation.

Hospital Course

The patient developed multidrug resistant (MDR) Pseudomonas aeruginosa pneumonia, persistent respiratory failure, and colistin-induced renal failure. We describe the use of intravenous bacteriophage therapy (BT) along with systemic antibiotics in this patient, lack of adverse events, and clinical resolution of infection with this approach. She did not have recurrence of pseudomonal pneumonia and CF exacerbation within 100 days following the end of BT and underwent successful bilateral lung transplantation 9 months later.

Conclusion

Given the concern for MDR P. aeruginosa infections in CF patients, BT may offer a viable anti-infective adjunct to traditional antibiotic therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fong SA, Drilling A, Morales S, et al. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418.CrossRefPubMedPubMedCentral Fong SA, Drilling A, Morales S, et al. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Hurley MN, Camara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J. 2012;40:1014–23.CrossRefPubMedPubMedCentral Hurley MN, Camara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur Respir J. 2012;40:1014–23.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hraiech S, Bregeon F, Rolain JM. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Dev Ther. 2015;9:3653–63. Hraiech S, Bregeon F, Rolain JM. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Dev Ther. 2015;9:3653–63.
4.
Zurück zum Zitat Essoh C, Blouin Y, Loukou G, et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE. 2013;8:e60575.CrossRefPubMedPubMedCentral Essoh C, Blouin Y, Loukou G, et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE. 2013;8:e60575.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Saussereau E, Vachier I, Chiron R, et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect. 2014;20:O983–90.CrossRefPubMed Saussereau E, Vachier I, Chiron R, et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect. 2014;20:O983–90.CrossRefPubMed
6.
Zurück zum Zitat Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–5.CrossRefPubMed Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–5.CrossRefPubMed
Metadaten
Titel
Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient
verfasst von
Nancy Law
Cathy Logan
Gordon Yung
Carrie-Lynn Langlais Furr
Susan M. Lehman
Sandra Morales
Francisco Rosas
Alexander Gaidamaka
Igor Bilinsky
Paul Grint
Robert T. Schooley
Saima Aslam
Publikationsdatum
17.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 4/2019
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01319-0

Weitere Artikel der Ausgabe 4/2019

Infection 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.